Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC001 in Advanced or Metastatic PDAC and Solid Tumors
NCT07909356Phase 1Not yet recruiting
- Sponsor
- Medicovestor, Inc.
- Start
- Dec 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADoBind MC001 in pancreatic ductal adenocarcinoma (PDAC) and solid tumor (2 arms), sponsored by Medicovestor, Inc. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) and Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) in Part A at 21 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ADoBind MC001
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT07909356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909356.